TY  - JOUR
AU  - Weller, Johannes
AU  - Zeyen, Thomas
AU  - Schäfer, Niklas
AU  - Schaub, Christina
AU  - Potthoff, Anna-Laura
AU  - Steinbach, Joachim P
AU  - Hau, Peter
AU  - Seidel, Clemens
AU  - Goldbrunner, Roland
AU  - Tabatabai, Ghazaleh
AU  - Vatter, Hartmut
AU  - Tzaridis, Theophilos
AU  - Schneider, Matthias
AU  - Herrlinger, Ulrich
TI  - The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial.
JO  - Journal of neuro-oncology
VL  - 164
IS  - 3
SN  - 0167-594X
CY  - Dordrecht [u.a.]
PB  - Springer Science + Business Media B.V
M1  - DKFZ-2023-02005
SP  - 749-755
PY  - 2023
N1  - 2023 Sep;164(3):749-755
AB  - The AVAglio trial reported a significant survival benefit for first line bevacizumab treatment in patients with IDH wildtype glioblastoma of the proneural gene expression subtype. We here aim to replicate these findings in an independent trial cohort.We evaluate the treatment benefit of bevacizumab according to gene expression subtypes of pretreatment tumor samples (n = 123) in the GLARIUS trial (NCT00967330) for MGMT unmethylated glioblastoma patients with Kaplan-Meier analyses, log-rank tests and Cox regression models.Employing the Phillips classifier, bevacizumab conferred a significant PFS advantage in patients with proneural IDH wild-type tumors (10.4 vs. 6.0 months, p = 0.002), but no OS advantage (16.4 vs. 17.4 months, p = 0.6). Multivariable analysis adjusting for prognostic covariates confirmed the absence of a significant OS advantage from bevacizumab (hazard ratio, 1.05, 95
KW  - Bevacizumab (Other)
KW  - Gene expression (Other)
KW  - Glioblastoma (Other)
KW  - Newly diagnosed glioblastoma (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37787906
DO  - DOI:10.1007/s11060-023-04470-9
UR  - https://inrepo02.dkfz.de/record/284416
ER  -